Teva TEVA · NYSE
$41.35 +1.55% (+$0.63)
Summary
37 / 100 · Bulios Score
What speaks for it
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- Repaying its net debt would take 5.1 years of operating profit.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 4.1 USD is left as net profit.
- Analysts expect revenue to fall by 4.5% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 67.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.7% a year over 5 years. Over the last 3 years it grew by 5.0% a year. For the next fiscal year analysts expect revenue to fall by 4.5%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 48 USD
- Research and development 5.7 USD
- Sales and administration 35 USD
- Taxes and other 7.4 USD
- Net profit 4.1 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 4.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 12.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 22
- Hold 20
- Sell 4
Today's price within the analysts' price targets
The average target of $47.33 is 14% above today's price. 48% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 85%
- Distribution Service 9.0%
- License 3.9%
- Product and Service, Other 2.5%
By region
- United States Segment 56%
- Europe Segment 31%
- International Markets 13%
Product brings in 85% of revenue. License grew fastest, by 43% a year.
Segments in detail